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and cardiovascular disease amongst others. Treatment effects and
cohort characteristics (mean age 63.1 years, diabetes duration
12.8 years, HbA1c 8.17%, BMI 30.3 kg/m2) were based on the
German cohort of the PREDICTIVE (Predictable Results and
Experience in Diabetes through Intensiﬁcation and Control to
Target: an International Variability Evaluation) study. Direct
medical costs were derived from published sources and expressed
in 2006 Euro (€) values. Projections were made over a 35-year
time horizon. Future costs and clinical beneﬁts were discounted
at 3.5% annually. Sensitivity analyses were performed.
RESULTS: Treatment with IAsp was projected to improve
quality-adjusted life expectancy by approximately 0.10 quality-
adjusted life years (QALYs) (6.06  0.09 versus 5.96  0.09
QALYs). Increased treatment costs with IAsp were partially
offset by cost savings due to reductions in the cumulative inci-
dence of diabetes-related complications. Over patient lifetimes,
mean direct medical costs were projected to increase by
approximately €1,274 per patient with IAsp versus HSI
(€45,423  1,354 versus €44,149  1,391). This resulted in
an incremental cost-utility ratio of €13,305 per QALY gained.
CONCLUSION: Over patient lifetimes, IAsp treatment was
projected to result in fewer diabetes-related complications
and improved quality-adjusted life expectancy compared to
HSI. Based on currently accepted willingness-to-pay limits, IAsp
would represent good value for money in the German setting.
ED3
DIFFERENCES IN HEALTH RELATED RESOURCE USE INTHE 6
MONTHS PRIORTO AND AFTER INSULIN INITIATION IN
PATIENTS WITHTYPE 2 DIABETES IN GERMANY AND
UNITED KINGDOM: DATA FROMTHE INSTIGATE STUDY
Timlin L1,Tynan A1, Simpson A1, Jones S2, Liebl A3
1Eli Lilly and Company Limited, Surrey, UK, 2The James Cook
University Hospital, Middlesborough, UK, 3Fachklinik Bad Heilbrunn,
Bad Heilbrunn, Germany
OBJECTIVES: An objective of the INSTIGATE study is to
describe the resource utilisation associated with care for type 2
diabetes in the 6 months before and after insulin initiation. This
abstract presents data from patients enrolled in Germany
and UK. METHODS: INSTIGATE is an ongoing prospective
European observational study investigating patients with type 2
diabetes who have initiated insulin during usual care. Data on
resource use for diabetes was collected at baseline retrospectively
for the 6 months prior to initiating insulin and at 3 and 6 months
following insulin initiation. RESULTS: In all, 509 patients were
enrolled in Germany and UK. 6 month follow-up data was
collected from 457 patients. The following changes in health care
professional consultations were observed in the 6 months before
and after insulin initiation: The % of patients with a visit to a
primary care doctor declined from 93.4% to 83.7% in Germany,
and in the UK from 79.4% to 48.2%. Visits to specialist nurses
increased in Germany from 52.3% to 91.4%, and in the UK from
77.5% to 81.7 % of patients. In both countries the % of patients
having phone calls with a specialist nurse increased; from 11.7%
to 50.6% in Germany and from 21.3% to 75.9% in UK. The %
of patients using a blood glucose monitor and the median weekly
number of test strips used increased in both countries, most
notably in Germany from 76.6% of patients testing 4 times a
week before insulin initiation to 99.6% of patients testing 21
times per week 6 months after insulin initiation. CONCLU-
SION: The type of health care professionals visited and nature of
the consultations changed in both countries following insulin
initiation; the % of patients having visits to primary care pro-
viders decreased and the % of patients having visits and phone
calls to specialist nurses increased.
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OBJECTIVES: This study, conducted in Type 2 diabetes mellitus
(T2DM), evaluated the cost utility of glargine versus NPH in
previously insulin naïve (IN) and non insulin naïve (NIN)
patients switching from NPH to insulin glargine in the UK using
observational data. The study assessed the combined effect of
HbA1c and hypoglycaemia reduction. METHODS: A discrete
event life time simulation based on UKPDS 68 was adapted to
include the effects of HbA1c and hypoglycaemia reduction using
published meta-regression results from 11 randomised clinical
trials. Direct costs and health utility (EQ5D) were derived from
published sources and the HODaR database respectively; costs
and beneﬁts were discounted at 3.5%. This model used the
demographic and efﬁcacy proﬁles of T2DM patients who were
IN or NIN who switched from NPH to glargine identiﬁed via the
THIN database. Analysis was conducted on 1,496 and 174 IN
and NIN patients respectively; the primary outcome measure was
Hba1c change. As hypoglycaemia was not directly collected from
the THIN database, sensitivity analysis was performed taking
into account HbA1c beneﬁt only. RESULTS: The mean age and
duration of diabetes at switch was 63 years and 7.5 years (IN)
and 70 years and 10.2 years (NIN) respectively. After adjustment
for baseline proﬁles IN patients starting glargine showed a sig-
niﬁcant reduction in HbA1c of 0.21% (p = 0.029) 12 months
post initiation versus NPH. For NIN patients switching from
NPH to glargine the adjusted HbA1c reduction was 0.46%
(p = 0.0093). The cost per QALY for a simulated cohort of
10,000 patients was £5,806 and £3,415 for IN and NIN patients.
In sensitivity analysis considering an HbA1c reduction only the
cost per QALY was £18,179 and £7,973 for IN and NIN patients
respectively. CONCLUSION: Based on real life observational
data, in both IN and NIN patients T2DM patients, glargine is
cost-effective compared to NPH.
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OBJECTIVES: This study tested a method to measure the vari-
ability of data among countries, and to assess the generalisability
of cost evaluation results. METHODS: The ﬁrst step of the
method consisted in identifying, within cost evaluations, all the
factors potentially responsible for variability among locations.
The second step consisted in selecting, among all potential trans-
ferability factors, the ﬁnal transferability factors which generated
variability, impacted on outcomes of economic evaluation, and
were both measurable and distinguishable from other factors.
The third step was the identiﬁcation of transferability areas
as sets of homogeneous ﬁnal transferability factors. Both the
Euclidean metric and Principal Components Analysis were used
in the fourth step to explore the generalisability of the results.
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